Biocon Limited(BSE:532523 NSE:BIOCON) ,Company Snapshot, Recent Developments, Latest News, Financials, Price Charts, Ratios, Contact Information

Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals

Home

News Centre

IPO

Markets	Companies	Research	Industries	E-Mail Page

my Last 5 Scrips
Company	BSE Price(Rs)	% Chg
Jindal S	245.80	2.52
Tata Stl	290.55	2.05
H D F C	665.05	1.14
Sterlite	85.25	2.65
Hindalco	104.20	2.66
Clear All	Clear Last

NSE Live
Nifty Live Prices Live Quotes Top Gainers/Losers Top 10 Turnover No Delivery Stocks

BSE Live
BSE30 Live Prices Live Quotes Top Gainers/Losers Top 10 Turnover No Delivery Stocks

Market Pulse
Leaders Laggards FII Activity Mutual Fund Activity Meetings

Results Watch
Results Calendar Results Announced

IPO Watch

Company
Snapshots Quotes Charts Financials Recent News Broker Research Meetings Research Tutorial Discussion Forum

Research
Research Reports

Sector Watch

Economy Watch

Snapshot-Biocon Limited

Biocon Limited

Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs and Formulations
BSE:532523	NSE:BIOCON	Bloomberg:BIOS@IN	Reuters:BION.BO
Market Lot: 1	Face Value: 5	ISIN Demat: INE376G01013

Quotes	Snapshot	Charts	Financials	Research	Recent News
Peer Group	AGM/AM	MF Holding	Discussion Forum	BSE/NSE Notices	BSE/NSE Deals

Recent Developments
14-FEB-13 Biocon, Asia's premier biotechnology company today announced that it has entered into a definitive agreement with Mylan for an exclusive strategic collaboration for the global development and commercialization of generic versions of its three insulin analog products. 25-JAN-13 Biocon, Asia's leading biotechnology enterprise announced today that the U.S. Pharmacopeial Convention (USP) has named Biocon chairman & managing director and... More..
Business Profile	Future Plans

One To One

Latest News

Biocon Q4 profit surges 2.5 times on one time gain -IRIS 26-Apr-13

Brief Financials (in Rs. Mn.)

Period ending (months)	31-Mar-2013 (12)	31-Mar-2012 (12)	31-Mar-2011 (12)
Net sales	18374.80	15048.00	15315.60
Other Income	514.70	665.50	255.10
Total Income	18889.50	15713.50	15570.70
Cost of goods sold	15323.10	12223.00	9824.60
OPBDIT	3566.40	3490.50	5746.10
PAT	2757.00	2555.00	4592.50
Gross Block	-	-	-
Equity capital	1000.00	1000.00	1000.00
EPS (Rs.)	14.08	0.00	23.49
DPS (Rs.)	-	-	-
BV (Rs.)	-	-	-
P/E range (x)	14.78 - 22.83	NA	11.58 - 19.78
Debt / Equity (x)	-	-	-
Operating margin (% of OI)	18.9	22.2	36.9
Net margin (% of OI)	14.6	16.3	29.5